Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer: a randomized, double blind, placebo-controlled study.

Inclusion Criteria:

• Objective diagnosis of colorectal cancer;
• Elective laparoscopic surgery for colorectal cancer
• Whatever the stage of cancer
• Antithrombotic prophylaxis with LMWH administered for 7±2 days after surgery

Exclusion Criteria:

• Age < 18 years
• Surgery for non-cancer disease
• Duration of surgery < 45 min
• Conversion to open surgery
• Other indication for anticoagulant therapy
• Known cerebral metastases
• Kidney or liver failure
• Known hemorrhagic diathesis or high risk for bleeding
• History of intracerebral bleeding or neurosurgery within 6 months
• History of heparin induced thrombocytopenia
• Pregnancy or lactation
• Refusal of informed consent.